Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for vrx
237.53
+4.26 (1.83%)
After Hours: 238.00 +0.47 (0.20%)
May 22, 7:44PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 232.03 - 238.49
52 week 106.00 - 238.49
Open 233.17
Vol / Avg. 1.95M/1.77M
Mkt cap 79.71B
P/E 80.38
Div/yield     -
EPS 2.96
Shares 342.27M
Beta 0.89
Inst. own 58%
Jul 29, 2015
Q2 2015 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 20, 2015
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting (Estimated)
May 19, 2015
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting - Webcast
Apr 29, 2015
Q1 2015 Valeant Pharmaceuticals International Inc Earnings Release
Apr 29, 2015
Q1 2015 Valeant Pharmaceuticals International Inc Earnings Call
Feb 23, 2015
Q4 2014 Valeant Pharmaceuticals International Inc Earnings Call
Feb 22, 2015
Q4 2014 Valeant Pharmaceuticals International Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 3.40% 11.04%
Operating margin 23.89% 23.11%
EBITD margin - 55.83%
Return on average assets 0.92% 3.36%
Return on average equity 5.03% 17.52%
Employees 16,800 -
CDP Score - -

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. In June 2014, Akorn Inc sold its subsidiary, ECR Pharmaceuticals (ECR) to Valeant Pharmaceuticals International, Inc. In July 2014, the Company acquired PreCision Dermatology, Inc.

Officers and directors

J. Michael Pearson Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Howard Bradley Schiller Chief Financial Officer, Executive Vice President, Director
Age: 53
Bio & Compensation  - Reuters
Pavel Mirovsky President and General Manager, Europe
Age: 64
Bio & Compensation  - Reuters
Robert Roswell Chai-Onn Executive Vice President, General Counsel and Chief Legal Officer, Head of Corporate and Business Development, Director
Age: 44
Bio & Compensation  - Reuters
Ari Kellen Executive Vice President, Company Group Chairman
Age: 51
Bio & Compensation  - Reuters
Laizer D. Kornwasser Executive Vice President, Company Group Chairman
Age: 44
Bio & Compensation  - Reuters
Brian M. Stolz Executive Vice President - Administration, Chief Human Capital Officer
Age: 39
Bio & Compensation  - Reuters
Robert A. Ingram Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Ronald Harold Farmer Independent Director
Age: 64
Bio & Compensation  - Reuters
Colleen A. Goggins Independent Director
Age: 60
Bio & Compensation  - Reuters